ECM
TCRR

Endurant Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Endurant Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,494
Closed -$591K – 75
2020
Q2 		$591K Buy
+38,494
New +$444K 0.03% 51

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Endurant Capital Management's TCRR Position: Q3 2020 in Review

Endurant Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2020, closing a stake of 38,494 shares — an estimated $591K sold.

Endurant Capital Management first reported a position in TCRR in Q2 2020 and held it in 1 quarter. The position peaked at $591K in Q2 2020. 82 funds tracked by Wall St. Rank hold TCRR as of Q3 2020.

  • Endurant Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Endurant Capital Management sold 38,494 TCR2 Therapeutics Inc. Common Stock shares in Q3 2020, an estimated $591K.
  • Endurant Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Endurant Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $591K in Q2 2020.
  • 82 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2020.

Based on Endurant Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.